- Aurobindo Pharma‘s revenue for the first quarter was 78.68 billion rupees, missing the estimated 81.97 billion rupees.
- Total costs for the company amounted to 67.69 billion rupees.
- Employee benefits expenses were recorded at 12.29 billion rupees, higher than the estimated 11.55 billion rupees.
- The finance cost stood at 977.5 million rupees, which was below the estimated 1.12 billion rupees.
- The company reported other income of 1.05 billion rupees.
- The stock has 23 buy recommendations, 1 hold recommendation, and 5 sell recommendations.
A look at Aurobindo Pharma Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Smartkarma Smart Scores provide a snapshot of Aurobindo Pharma‘s long-term outlook across key factors. With strong scores in Value and Resilience, the company appears well-positioned for sustained growth and stability. Aurobindo Pharma‘s focus on manufacturing and marketing a range of essential generic drugs, including antibiotics and anti-ulcerants, underscores its commitment to providing critical healthcare solutions. While scoring moderately for Dividend, Growth, and Momentum, the company’s solid foundation in value and resilience bodes well for its overall trajectory.
Aurobindo Pharma Limited, a leading manufacturer of oral and sterile antibiotics along with various generic drugs, showcases a robust profile in the pharmaceutical industry. Known for producing vital medications like penicillin drugs and antibiotics, the company also offers essential formulations that cater to diverse healthcare needs. With a strategic emphasis on value and resilience, Aurobindo Pharma positions itself as a key player in the sector, poised for long-term success and growth.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
